<?xml version="1.0" encoding="UTF-8"?>
<p>Further improvement of RGC100 resulted in appearance of the drug RGIC100—Poly(GI):PolyC; one its chain was PolyC, and the complementary chain contained G and I random quantitative combinations from 1 to 
 <italic>n</italic> − 1, where 
 <italic>n</italic> is the total number of nucleotides in the complementary chains. The pharmaceutical composition contains the active component Poly(GI):PolyC of at least 45 bp in length in combination with pharmaceutically acceptable carriers, excipients and/or solvents. According to the authors of the patent [
 <xref ref-type="bibr" rid="CR68">68</xref>], Poly(GI):PolyC can be used for activation of innate immunity, prevention and treatment of infectious and neoplastic diseases.
</p>
